Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Gastrointestinal Stromal Tumors


Other Names for this Disease

  • Gastrointestinal Stromal Sarcoma
  • GIST
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Newline Maker

How might gastrointestinal stromal tumors be treated?

For patients with primary, localized gastrointestinal stromal tumors, surgery with complete excision is the treatment of choice.[1] However, surgery has limited efficacy in the treatment of recurrent and metastatic gastrointestinal stromal tumors. These tumors are also resistant to both chemotherapy and radiotherapy. In the pre-imatinib era, the 5-year survival rate after the surgical resection of gastrointestinal stromal tumors was only 43%–80% as there was really no efficient method to cure the disease.[2] The addition of imatinib as part of the treatment of unresectable or recurrent gastrointestinal stromal tumors has improved the management of this condition and resulted in improved patient survival.[1][2]

Last updated: 4/27/2010

References
  1. Choi WH, Kim S, Hyung WJ, et al.. Yonsei Med J. June 30, 2009; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2703769/?tool=pubmed. Accessed 4/27/2010.
  2. Cao H, Zhang Y, Wang M, et al.. Chinese Medical Journal. 2010; http://www.cmj.org/Periodical/paperlist.asp?id=CMJLW2010120518763408057&linkintype=pubmed. Accessed 4/27/2010.


Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Gastrointestinal Stromal Tumors. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Imatinib mesylate
Trade Name
(Manufacturer Name)
Gleevec®
(Novartis Pharmaceuticals Corp.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST)
More Information about this product Drug Information Portal

Generic Name Regorafenib
Trade Name
(Manufacturer Name)
Stivarga
(Bayer HealthCare Pharmaceuticals, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Pazopanib
Trade Name
(Manufacturer Name)
Votrient
(GlaxoSmithKline)
Indication
The FDA has approved this product to be used in this manner.
Advanced soft tissue sarcoma (STS) who have received prior chemotherapy.
More Information about this product Drug Information Portal
Medline Plus Health Information

Other Names for this Disease
  • Gastrointestinal Stromal Sarcoma
  • GIST
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.